Cyteir Therapeutics Stock Current Valuation
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
Valuation analysis of Cyteir Therapeutics helps investors to measure Cyteir Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Cyteir Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Cyteir Therapeutics is based on 3 months time horizon. Increasing Cyteir Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cyteir Therapeutics' intrinsic value may or may not be the same as its current market price of 2.76, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.76 | Real 2.13 | Hype 2.76 | Naive 2.5 |
The intrinsic value of Cyteir Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cyteir Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cyteir Therapeutics helps investors to forecast how Cyteir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyteir Therapeutics more accurately as focusing exclusively on Cyteir Therapeutics' fundamentals will not take into account other important factors: Cyteir Therapeutics Company Current Valuation Analysis
Cyteir Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cyteir Therapeutics Current Valuation | (20.89 M) |
Most of Cyteir Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyteir Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Cyteir Therapeutics has a Current Valuation of (20.89 Million). This is 100.15% lower than that of the Biotechnology sector and 100.45% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.13% higher than that of the company.
Cyteir Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in current valuation category among its peers.
Cyteir Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) | |||
| EBITDA | (33.41 M) | |||
| Net Income | (33.22 M) | |||
| Cash And Equivalents | 166.4 M | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 889 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 19.95 X | |||
| Book Value Per Share | 3.47 X | |||
| Cash Flow From Operations | (25.79 M) | |||
| Short Ratio | 3.07 X | |||
| Earnings Per Share | (0.93) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 46 | |||
| Beta | 0.096 | |||
| Market Capitalization | 108.71 M | |||
| Total Asset | 153.23 M | |||
| Retained Earnings | (138.11 M) | |||
| Working Capital | 143.89 M | |||
| Current Asset | 834.8 M | |||
| Current Liabilities | 366.9 M | |||
| Net Asset | 153.23 M |
About Cyteir Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyteir Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |